Chemical Compound
2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-; (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide; Dacomitinib; PF 00299804; PF 299; PF 299804
CAS Registry Number
1110813-31-4
Primary record
2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-; (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide; Dacomitinib; PF 00299804; PF 299; PF 299804
- 库存
- 2,973 克
- 纯度
- 99.2 %
- CAS
- 1110813-31-4
化合物标识与属性
- CAS
- 1110813-31-4
- PubChem CID
- 11511120
- SMILES
- COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
- Canonical SMILES
- COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1
名称与同义词
- Dacomitinib
- 1110813-31-4
- Vizimpro
- dacomitinibum
- Dacomitinib anhydrous
- Dacomitinib [USAN]
- Dacomitinib monohydrate
- Dacomitinib (INN)
- Dacomitinib (PF299804)
- DACOMITINIB HYDRATE
- PF-00299804
- Dacomitinib (PF299804, PF299)
- Dacomitinib (Standard)
- Dacomitinib [USAN:INN]
- PF299804
- RefChem:585148
- C24H25ClFN5O2
- DACOMITINIB [INN]
- D06XXH
- UNII-2XJX250C20
- Dacomitinib, PF299804
- 2XJX250C20
- MFCD19443734
- SCHEMBL33147
- DACOMITINIB [WHO-DD]
- cc-194
- MLS006011275
- CHEBI:132268
- DTXSID50149493
- PF-299
- pf00299804
- GTPL7422
- orb1305418
- PF-299804
- CHEMBL2110732
- DTXCID8071984
- PF-00299804 dacomitinib
- SCHEMBL29354322
- SCHEMBL29377735
- CHEBI:91466
- EX-A030
- L01XE47
- QCR-174
- BDBM112499
- Dacomitinib (PF-00299804)
- GLXC-90191
- HMS5081D15
- PF299
- AMY21292
- AOB87383
- AOB87735
- BCP02530
- EGFR Inhibitor PF-00299804
- PF-00299804-03
- ABP000126
- EBC-24037
- HY-13272R
- NSC765888
- NSC800084
- PF-804
- s2727
- ZINC72266312
- (E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide
- AKOS025401818
- PF 00299804-03
- ACN-031538
- CCG-264987
- CS-0500
- DB11963
- FD64992
- NSC-765888
- NSC-800084
- RL00451
- SDCCGSBI-0646934.P001
- 1042385-75-0
- CID11511120
- US8623883, No. 2
- NCGC00263185-09
- NCGC00263185-10
- AC-25915
- AS-57686
- BC261945
- BP-43638
- DA-56723
- HY-13272
- SC-94589
- SMR004703025
- PF299804|||PF299
- AB0035896
- (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide
- 5092U85G58
- A8319
- D5450
- FT-0696499
- NS00072953
- SW219155-1
- Y0338
- J3.341.567B
- PF 00299804
- A11051
- D09883
- Dacomitinib (PF299804, PF-00299804)
- PF-299804 (Dacomitinib PF-00299804)
- Q-4059
- EN300-7406881
- PF-299804 (Dacomitinib,PF-00299804)?
- A848337
- A896262
- (2e)-N-{4-[(3-Chloro-4-Fluorophenyl)amino]-7-Methoxyquinazolin-6-Yl}-4-(Piperidin-1-Yl)but-2-Enamide
- BRD-K57169635-001-04-5
- Q17130597
- (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
- B0084-452473
- 1110813-31-4 pound not PF 299804 pound not PF-299804
- (2E)-N-(4-((3-CHLORO-4-FLUOROPHENYL)AMINO)-7-METHOXYQUINAZOLIN-6-YL)-4-PIPERIDIN-1-YLBUT-2-ENAMIDE
- (2E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide
- 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-, (2E)-
- Dacomitinib, 98%, a potent irreversible ErbB inbibitor - 10MG 10mg
- (E)-N-[4-(3-Chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidino-2-buteneamide
- (2E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide
- (2E)-N-(4-(3-Chloro-4-fluorophenyl)amino)7-methoxyquinazolin-6-yl)4-(piperidin-1-yl)but-2-enamide monohydrate
- (E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-piperidin-1-ylbut-2-enamide
- (E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide
- (E)-N-[4-(3-chloro-4-fluoro-anilino)-7-methoxy-quinazolin-6-yl]-4-(1-piperidyl)but-2-enamide
- (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide,hydrate
- (E)-N-[4-[(3-chloro-4-fluoro-phenyl)amino]-7-methoxy-quinazolin-6-yl]-4-(1-piperidyl)but-2-enamide
- (E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide
- (E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
- 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-, hydrate (1:1), (2E)-
- 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-
- 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-; (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide; Dacomitinib; PF 00299804; PF 299; PF 299804